# ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

> **NCT01481194** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 35 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01481194
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-05
- **Final completion:** 2018-08-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01481194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01481194, "ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01481194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*